The role of a Medical Science Liaison (MSL) is of growing importance to pharmaceutical, biotechnology, diagnostic and medical device companies.
Perspective
Africa comprises over 20% of the world's land mass and has a population in excess of a billion. Africa bears the greatest burden of disease in the world and the lowest life expectancy [1] , however the pharmaceutical industry derives only ~2% of their global market share from Africa [2] . The reasons for the aforementioned discrepancies are multifactorial, including evolving regulations, infiltration of counterfeit medicines, reliance upon or preference for traditional medicines, supply chain constraints and socio-economic conditions. Owing to the large population, the prevalence of infectious disease (including HIV/AIDS, malaria and tuberculosis) and growing non-communicable as well as lifestyle disease, the need for innovative therapies to lessen morbidity and mortality is substantial. The American and European pharmaceutical market growths are tending to plateau; conversely growth in the developing world is fast and the African pharmaceutical industry is expected to be worth $40-60 billion by 2020 [3] . This growth in volume, along with new launches of sophisticated therapies (including biologics, rational combinations and intelligent formulations) requires innovative pharmaceutical companies to increasingly use skilled Medical Science Liaisons (MSLs) to generate and disseminate pertinent scientific data. MSLs also known as Regional Medical Advisors amongst a host of other alternate titles [4, 5] are generally highly credentialed (MD, PhD, pharmacists, and in some instances medical specialists) [5] and can have peer to peer discussions with external experts. Although the MSL role is considered relatively new in Africa, the role begun in developed countries in the late 1960's and although still evolving is currently advanced [6, 7] . Recently, for the first time the roles and expectations for a MSL have been somewhat harmonized through the publication of an international guideline document by the Medical Science Liaison Society (MSLS) [5] . The purpose of this paper is to describe the role and responsibilities of MSLs (as collated from various publications, societies, round table discussions and leaning on the experiences of the authors); to describe the MSL-physician relationship (the nature, content and value of this engagement); to describe the differences between the MSL and other field based functions and to outline future needs and directions to maximally utilise the MSL resource. Table 1 lists the key MSL competencies, roles and responsibilities. 
Conclusion
As innovative, complex and precision therapies emerge from development pipelines, and as the pharmaceutical industry grow in Africa, MSLs are suited to fulfil unmet data needs in an ethical and compliant way. Ultimately, the success of the MSL role in achieving pre-defined, non-commercial focused performance metrics will be determined by the extent to which individual organisations identify and learn from specific regional challenges and are capable of innovating or embracing approaches to maximize meaningful scientific engagement. 
